Latest Analysis Report on Ertapenem Injection Market 2020-2025 by Growth Factor with Top Companies like Merck, Endo, Aurobindo Pharma, ACS Dobfar

Global Ertapenem Injection Market 2020-2025 examines the market in detail along with focusing on significant market dynamics for the key players in the market. This research report offers granulated yet in-depth analysis of revenue share, market segments, revenue estimates and various regions across the globe.

Global Ertapenem Injection Market overview:

Ertapenem is a carbapenem antibiotic medication for the treatment of infections of the abdomen, the lungs, the upper part of the female reproductive system, and diabetic foot, used in the form of infusions or injections. The most common side effects include diarrhoea, nausea (feeling sick), headache, and problems around the area where the medicine is infused. It can significantly reduce the concentrations of valproic acid, an anti-seizure medication, in the blood to the point where it loses its effectiveness. The Global Ertapenem Injection Market is segmented on the basis of Product Type, Application, End Use Industry and Region. This report also covers all the regions and countries of the world, which shows a regional development status, including market size.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/244808 .

On the Basis of Product Type segment, the Ertapenem Injection Market is sub segmented into INVANZ and Generic Version. Based on End Use Industry segment, the Ertapenem Injection Market is segmented as Adult and Pediatric.

There are several manufacturers of Ertapenem Injection in Europe and North America. In North America, the demand for Ertapenem Injection is primarily driven by the Healthcare sector. Among the countries in Asia Pacific, the demand was substantially high in developing countries such as China and India.

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Ertapenem Injection Market Report 2020” @ https://www.businessindustryreports.com/buy-now/244808/single .

Top Industry News:

Endo to Acquire BioSpecifics to Enhance Profitability of XIAFLEX and Qwo on 19 October 2020 -- Endo International plc today announced it has agreed to acquire all of the outstanding shares of BioSpecifics Technologies Corp., a commercial-stage biopharmaceutical company, for $88.50 in cash per share, or an estimated enterprise value of approximately $540 million (net of approximately $120 million in cash acquired) at the anticipated time of deal closure. Endo has had a strategic relationship with BioSpecifics since 2004. Under the terms of the relationship, BioSpecifics receives a royalty stream from Endo related to Endo's collagenase-based therapies, which currently include XIAFLEX, marketed by Endo Pharmaceuticals, for the treatment of Dupuytren's contracture and Peyronie's disease, and Qwo, the first FDA-approved injectable treatment for cellulite, which is expected to be launched by Endo Aesthetics in Spring 2021.

"Acquiring BioSpecifics is consistent with our strategic priority to expand and enhance our portfolio through additional investment in the significant long-term growth potential of both XIAFLEX and QWO - two of our most durable and differentiated products," said Blaise Coleman, President and Chief Executive Officer of Endo. "This transaction will also immediately enhance Endo's adjusted EBITDA and create significant value for shareholders of both organizations."

Under the terms of the merger agreement, Endo, through a wholly owned subsidiary, will commence an all-cash tender offer to acquire 100 percent of the outstanding common stock of BioSpecifics for $88.50 per share. The Edwin H. Wegman Marital Trust has entered into a Support Agreement committing it to tender its shares into the tender offer. The closing of the tender offer will be subject to certain conditions, including that not less than a majority of shares of BioSpecifics common stock are tendered, the expiration of the waiting period under antitrust laws and other customary conditions. Upon the successful completion of the tender offer, Endo's acquisition subsidiary will be merged into BioSpecifics, and any remaining shares of BioSpecifics will be canceled and converted into the right to receive the same consideration payable pursuant to the tender offer. The transaction is expected to close in late 2020 and Endo expects to fund the transaction with cash on hand. The transaction has been unanimously approved by the boards of directors of both companies.

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/244808 .

Major Key Players:

Some of the Ertapenem Injection Market manufacturers involved in the market are Merck, Endo, Aurobindo Pharma, ACS Dobfar in World, effective mergers are some of the strategies adopted by the Ertapenem Injection Market manufacturers. New product launches and continuous technological innovations are the Ertapenem Injection Market strategies adopted by the major players.

Table of Contents:

1 Ertapenem Injection Product Definition
2 Global Ertapenem Injection Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Ertapenem Injection Shipments
2.2 Global Manufacturer Ertapenem Injection Business Revenue
2.3 Global Ertapenem Injection Market Overview
3 Manufacturer Ertapenem Injection Business Introduction
3.1 Merck Ertapenem Injection Business Introduction
3.1.1 Merck Ertapenem Injection Shipments, Price, Revenue and Gross profit 2014-2019
3.1.2 Merck Ertapenem Injection Business Distribution by Region
3.1.3 Merck Interview Record
3.1.4 Merck Ertapenem Injection Business Profile
3.1.5 Merck Ertapenem Injection Product Specification
3.2 Endo Ertapenem Injection Business Introduction
3.2.1 Endo Ertapenem Injection Shipments, Price, Revenue and Gross profit 2014-2019
3.2.2 Endo Ertapenem Injection Business Distribution by Region
3.2.3 Interview Record
3.2.4 Endo Ertapenem Injection Business Overview
3.2.5 Endo Ertapenem Injection Product Specification
3.3 Aurobindo Pharma Ertapenem Injection Business Introduction
3.3.1 Aurobindo Pharma Ertapenem Injection Shipments, Price, Revenue and Gross profit 2014-2019
3.3.2 Aurobindo Pharma Ertapenem Injection Business Distribution by Region
3.3.3 Interview Record
3.3.4 Aurobindo Pharma Ertapenem Injection Business Overview
3.3.5 Aurobindo Pharma Ertapenem Injection Product Specification
3.4 ACS Dobfar Ertapenem Injection Business Introduction

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.